Muhamad Alhaj Moustafa, MD
Hematology & Oncology · Jacksonville, FLNPI 1023403201
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,743 of the $21,500 with a category attached, or 68.6%. 27 manufacturers reported payments, led by Genentech USA, Inc. at 25.5% of the total. 2025 is the largest year on record at $8,195, 2.2 times the $3,692 reported in 2019.
Across 82 payments — averaging $262.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$5K
- Aurobindo Pharma USA, Inc.$5K
- Acrotech Biopharma Inc.$5K
- Daiichi Sankyo Inc.$780
- AbbVie$692
- Beigene USA, Inc.$675
- plus $4K from 21 others
Across 43 payments — averaging $30,558 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$424K
- E.r. Squibb & Sons, L.L.C.$294K
- Acrotech Biopharma Inc.$279K
- Genentech, Inc.$176K
- Gamida Cell Inc.$95K
- Gilead$31K
- plus $16K from 1 others
What the payments were for
- Consulting fees$14,74369%
- Speaking & faculty fees$1,5007%
- Travel & lodging$1,0585%
- Food & beverage$3,05814%
- Education$1,1415%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 8 | $5,476 |
| Aurobindo Pharma USA, Inc. | 9 | $4,996 |
| Acrotech Biopharma Inc. | 7 | $4,623 |
| Daiichi Sankyo Inc. | 3 | $780 |
| AbbVie | 4 | $692 |
| Beigene USA, Inc. | 1 | $675 |
| AstraZeneca(2 entities) | 5 | $668 |
| Seagen Inc. | 7 | $561 |
| CSL Behring | 1 | $500 |
| Kyowa Kirin, Inc. | 6 | $456 |
| Amgen | 7 | $405 |
| Bristol Myers Squibb | 3 | $251 |
| Lilly USA, LLC | 4 | $248 |
| Pfizer | 4 | $209 |
| Genentech, Inc. | 1 | $137 |
| Ipsen Biopharmaceuticals, Inc | 1 | $135 |
| Eli Lilly | 1 | $122 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Gilead | 1 | $112 |
| Beone Medicines USA, Inc. | 1 | $91 |
| Epizyme, Inc. | 1 | $87 |
| Eisai Inc. | 1 | $55 |
| Puma Biotechnology, Inc. | 1 | $23 |
| Astellas Pharma Global Development | 1 | $23 |
| Janssen Scientific Affairs, LLC | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,500 in reported general payments places this provider in the 70th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 27 | $386,792 |
| EliquisApixaban | 22 | $13,649 |
| Acyclovir | 98 | $1,002 |
| Ondansetron Hcl | 12 | $205 |
| Prochlorperazine Maleate | 20 | $198 |
| Olanzapine | 12 | $115 |
| Prednisone | 39 | $105 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $55 |
| Allopurinol | 12 | $32 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $675 | $386,79227 claims |
| PfizerEliquis | $209 | $13,64922 claims |
| Lilly USA, LLCOlanzapine | $248 | $11512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Jacksonville
- Edith PerezJacksonville$1.1M
- Vamsidhar VelchetiJacksonville$966K
- Arnab BasuJacksonville$440K
- Sikander AilawadhiJacksonville$179K
- James ForanJacksonville$164K
- Asher Chanan KhanJacksonville$109K
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.